Motoyuki Sugai
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (13)
Year:
2026
Year:
2026
Background Streptococcus agalactiae (Group B Streptococcus, GBS) is a leading cause of invasive neonatal and infant infections, including sepsis and meningitis. This study aimed to estimate the vaccine coverage and characterize the genomic features of pediatric invasive GBS in Japan. Methods We conducted a nationwide, multicenter, retrospective genomic surveillance study involving 237 GBS isolates from sterile specimens of children aged ≤15 years across 35 hospitals in Japan between 2004 and 2023. Serotyping, antimicrobial susceptibility testing, and whole-genome sequencing were performed. Results The estimated vaccine coverage was 98.3% for the hexavalent polysaccharide vaccine and 94.9% for the GBS-NN/NN2 protein vaccine. Erythromycin and clindamycin resistance were observed in 61.2% and 43.5%, respectively. Among the 75 CC17 isolates, 59 (78.7%) contained only PI-2B and harbored both ermB and tetO, indicating the predominance of a multidrug-resistant clone. Single nucleotide polymorphism–based analysis revealed evidence of nosocomial transmission and persistent regional circulation, particularly within the ST17 and ST23 lineages. Conclusions This study suggests that current maternal GBS vaccine candidates would provide broad coverage for pediatric invasive infections in Japan. The identification of persistent and regionally disseminated lineages highlights the importance of investigating potential, yet, poorly understood, transmission routes, including environmental reservoirs, to inform future prevention strategies.
Year:
2026
Year:
2025
The ftsI locus of gram-negative bacteria encodes penicillin-binding protein 3 (PBP3), a common target of β-lactam antibiotics. Recent genomic surveillance of carbapenem-resistant Pseudomonas aeruginosa revealed that 17% of strains possessed nonsynonymous substitution in ftsI . However, the contribution of ftsI nonsynonymous substitution alone to the antimicrobial susceptibility of P. aeruginosa has not been formally evaluated. Therefore, we assessed the effect of ftsI nonsynonymous substitutions alone on β-lactam susceptibility in recombinant P. aeruginosa strains. The nonsynonymous substitutions C265G (Leu89Val), C1379T (Met460Thr), T1412G (Val471Gly), C1510T (Arg504Cys), C1579A (Pro527Thr), C1579T (Pro527Ser), C1599A (Phe533Leu), and G1609C (Val537Leu) were introduced into ftsI in an antimicrobial-susceptible strain via homologous recombination. Then, their β-lactam susceptibilities were investigated using the broth microdilution method and growth parameter analysis for the growth curves. The introduction of the N-terminal Leu89Val mutation did not alter β-lactam susceptibility. By contrast, the introduction of penicillin-binding (PB) domain mutations (Met460Thr, Val471Gly, Arg504Cys, Pro527Thr, Pro527Ser, Phe533Leu, or Val537Leu) reduced the susceptibility to meropenem and doripenem by two- to eightfold in MIC. Arg504Cys, the most common mutation encountered clinically, reduced susceptibility to cefepime by fourfold. Growth parameter analysis revealed that, conversely, these PB domain mutations generally increase the susceptibility to cefiderocol and piperacillin. The cocrystal structures of PBP3 with β-lactams suggest that the positions of PB domain mutations can affect the mobility of previously proposed key residues, namely, Tyr409, Arg489, Tyr503, Tyr532, Phe533, and the KSGT motif, via intramolecular interactions. These data demonstrated that seven specific variants in ftsI are genetic signals of bacterial adaptation to carbapenems. IMPORTANCE Previous studies have reported the occurrence of ftsI mutations under various genetic backgrounds in Pseudomonas aeruginosa clinical isolates. However, the nature of ftsI mutations by themselves has not been thoroughly investigated under a common genetic background using recombinant strains. This study presents experimental data on the effect of ftsI point mutations alone on bacterial susceptibility to a wide range of antipseudomonal β-lactams. This study found that seven specific penicillin-binding domain mutations in FtsI/PBP3 reduced the efficacy of carbapenems but increased the efficacies of piperacillin and cefiderocol. This key finding will facilitate the development of therapeutic options for carbapenem-resistant P. aeruginosa -associated infections. Furthermore, this study contributes to the development of a reliable database collating resistance-associated point mutations, which would aid the interpretation of genomic data on P. aeruginosa clinical isolates.
Year:
2025
Extended-spectrum β-lactamase-producing Escherichia coli (ESBL-Ec) poses a substantial public health challenge, particularly in developing countries where antimicrobial resistance is a growing concern. Although extensive research has documented the prevalence and impact of ESBL-Ec in clinical settings and farm animals, the intricate relationship between poultry farming practices and human health remains unclear. To elucidate the genomic relationships between isolates from chickens and humans, we conducted a whole-genome sequencing analysis of 200 E. coli isolates derived from chickens, chicken farmers, and non-farmer volunteers in Lombok, Indonesia. The isolates exhibited considerable diversity, with 78 distinct sequence types (STs) identified by multilocus sequence typing. Of these, 35% ( n = 70) and 6% ( n = 12) were positive for ESBL and AmpC-type β-lactamase genes, respectively, with bla CTX-M-55 being the most prevalent ( n = 41). The most prevalent STs among those carrying ESBL or AmpC genes were ST48, ST1485, ST1727, and ST2690. Phylogenetic analysis of publicly available data indicated that ST1485, ST1727, and ST2690 strains had an indigenous spread in this region, whereas the ST48 isolates originated from different sources. The bla CTX-M-55 gene was identified in 22 different STs, predominantly carried by an IncHI1A-type plasmid, suggesting horizontal transmission of the plasmid over the clonal barrier. Long-read sequencing analysis of representative isolates revealed the presence of additional resistance genes against different classes of antibiotics, suggesting that the acquisition of the IncHI1A-type plasmid contributes to multidrug resistance in recipient clones. Our analysis provides unique insights into the dissemination of multidrug-resistant ESBL-Ec strains in Lombok, where humans and chickens are in close proximity. IMPORTANCE We performed a genomic comparison of ESBL-producing E. coli (ESBL-Ec) isolated from chickens, chicken farmers, and non-farmers on Lombok Island, where indigenous chicken farming, which involves close proximity of humans and chickens, is a major industry. The detection of the same ESBL-Ec clones in both chickens and farmers indicated the potential of a zoonotic transmission pathway for antibiotic-resistant bacteria. Moreover, the presence of a common plasmid carrying an ESBL gene along with other antimicrobial resistance genes in various E. coli clonal groups highlights the dissemination of resistance determinants within both poultry and human populations. This cross-species amplification of antimicrobial resistance poses a substantial risk to public health, as it can lead to the proliferation of multidrug-resistant bacterial infections, complicating treatment options and increasing the burden on healthcare systems. Addressing these issues is crucial for implementing effective antimicrobial stewardship and improving biosecurity practices in poultry farming.
Year:
2025
Bacteriocins, which are antimicrobial factors produced by bacteria, are expected to be candidates for a novel class of antimicrobial agents against antimicrobial-resistant bacteria, including methicillin-resistant Staphylococcus aureus . To evaluate its effectiveness, the examination of susceptibility using multiple clinical isolates is necessary. In this study, we focused on epidermin, a class I bacteriocin produced by Staphylococcus epidermidis . Among the 146 S. aureus clinical isolates, 77% did not show susceptibility to epidermin, but the susceptibility of some of the strains was significantly higher. Knowing that the two-component regulatory system BraRS affects the susceptibility to epidermin, we analyzed the inducibility of the effector gene vraD in susceptible strains and found that its ability is lost in highly susceptible strains. Some of these strains harbor frameshift or nonsense mutations in BraR, BraA and BraB. Interestingly, the vraDE genes with 35,005 bp neighboring genomic regions, including the icaRADBC and histidine biosynthesis operons, were lost in some highly susceptible strains. In addition, all the vraDE -deficient strains were CC121, and IS 1181 sequences located immediately upstream and downstream of the deleted region were found in some vraDE -positive CC121 strains. The deleted region was replaced by one copy of the IS 1181 sequence in vraDE -deficient strains. Subculturing of the vraDE -positive CC121 strain generated a vraDE- deficient mutant with increased susceptibility to epidermin at a rate of approximately 1%, suggesting that recombination between IS 1181 sequences results in the deletion of the genomic region, including vraDE, in some CC121 strains.
Year:
2025
BACKGROUND Ciprofloxacin resistant Klebsiella pneumoniae is common or emerging in many geographies, and knowledge of local resistance rates is important for empirical therapy. Whilst there are known K. pneumoniae ciprofloxacin resistance determinants, there is a lack of systematic data on the effect of determinants, alone and in combination, and there are no publicly accessible tools for predicting resistance from whole genome sequence data. METHODS The KlebNET-GSP AMR Genotype-Phenotype Group aggregated a matched genotype-phenotype dataset of n=12,167 K. pneumoniae species complex ( Kp SC) isolates from 27 countries between 2001-2021. We developed a rules-based classifier to predict ciprofloxacin resistance by categorizing the number of quinolone resistance determining regions mutations in gyrA and parC , the number of plasmid-mediated quinolone resistance genes, and the presence/absence of aac(6ʹ)-Ib-cr (which can acetylate ciprofloxacin). Predictive performance was assessed using the discovery dataset, for which we re-phenotyped discrepant isolates; and validated using externally contributed datasets (n=7,030 Kp SC isolates). RESULTS The rules-based classifier predicted R vs S/I with categorical agreement, sensitivity, and specificity >96%, and major/very major error rates <4%. Performance was similar across diverse Kp SC sources (human, animal, other), species, and intra-species lineages. External validation of the classifier yielded overall 93.12% categorical agreement [95% confidence interval (CI), 92.50-93.74%], 8.65% major errors [95% CI, 7.34-9.97%], and 6.20% very major errors [95% CI, 5.51-6.90%]. We implemented the classifier in Kleborate, a command-line tool that is integrated into the Pathogenwatch web platform. Using this to assess the global distribution of ciprofloxacin resistance determinants in Kp SC genomes available in Pathogenwatch (n=31,319, from 109 countries between years 2000-2023), we observed a significant positive association between national quinolone consumption rates and predicted ciprofloxacin resistance (R 2 =0.20, p=0.004). CONCLUSIONS Ciprofloxacin resistance phenotypes can be reasonably predicted from genotypes, which is sufficient for informing surveillance. However, unexplained resistance remains and accuracy is insufficient for clinical applications. We demonstrate the value of aggregating genotype-phenotype data to explore resistance mechanisms and develop predictors, but highlight complexities in combining phenotype data from different assays and standards.
Year:
2025
Staphylococcus species in food produce Staphylococcal enterotoxins (SEs) that cause Staphylococcal food poisoning (SFP). More than 20 SE types have been reported, among which Staphylococcal enterotoxin A (SEA) has been recognized as one of the most important SEs associated with SFP. However, the regulatory mechanisms underlying its production remain unclear. Previously, we identified a major SFP clone in Japan, CC81 subtype-1, which exhibits high SEA production. In this study, we attempted to identify the factors contributing to this phenomenon. Thus, we demonstrated that the attenuation of the activity of endogenous regulator, Staphylococcal accessory regulator S (SarS), and the lysogenization of a high SEA-producing phage contributed to this phenomenon in CC81 subtype-1. Furthermore, our results indicated that SarS could directly bind to the promoter upstream of the sea gene and suppress SEA expression; this low SarS repression activity was identified as one of the reasons for the high SEA production observed. Therefore, we revealed that both exogenous and endogenous factors may probably contribute to the high SEA production. Our results confirmed that SE production is a fundamental and critical factor in SFP and clarified the associated production mechanism while enhancing our understanding as to why a specific clone frequently causes SFP. IMPORTANCE The importance of this study lies in its unveiling of a molecular regulatory mechanism associated with the most important food poisoning toxin and the evolution of Staphylococcal food poisoning (SFP)-associated clone. SFP is primarily caused by Staphylococcus aureus , with Staphylococcal enterotoxin A (SEA) being commonly involved in many cases. Thus, SEA has been recognized as a major toxin type. However, despite almost a century since its discovery, the complete mechanism of SEA production is as yet unknown. In this study, we analyzed an SEA-producing SFP clone isolated in East Asia and discovered that this strain, besides acquiring the high SEA-producing phage, exhibits remarkably high SEA production due to the low activity of SarS, an intrinsic regulatory factor. This is the first report documenting the evolution of the SFP clone through the coordinated action of exogenous mobile genetic factors and endogenous regulators on this notorious toxin.
Year:
2024
The extended-spectrum β-lactamase (ESBL) gene, bla VEB-1 , was identified for the first time in an Escherichia coli clinical isolate, JARB-RN-0061, from blood cultures in a Japanese general hospital in 2021. The isolate exhibited high resistance to broad-spectrum cephalosporins, including ceftazidime (MIC >128 mg/L) and cefepime (MIC = 16 mg/L). bla VEB-1 was identified during whole-genome sequencing and characterization of the isolate. JARB-RN-0061 belonged to the B2-O2:K1:H7-ST95- fimH 41 lineage and was classified as presumptive extraintestinal pathogenic E. coli (ExPEC) and uropathogenic E. coli (UPEC). Moreover, the strain harbored multiple virulence genes on the chromosome. The Col156/IncFIB(AP001918)/IncFII(29)-type plasmid (114,216 bp), with clbB and tcpC genes involved in bacteremia, was unique to the fimH 41 subclone. The bla VEB-1 gene was located on a non-typeable and non-conjugative plasmid, pJARB-RN-0061_VEB-1 (17,093 bp). It was embedded in the class 1 integron In1883-like, with multidrug resistance gene cassettes for aacA4 , aadB , cmlA5 , qnrVC4 , and dfrA14 . Notably, comparative analysis of the complete sequence of plasmid pJARB-RN-0061_VEB-1 revealed that it was highly homologous to the bla VEB-1 -harboring plasmid, pMS2H7VEB-1 (100% coverage and 99.99% identity), except for the Tn3 family transposon (4,931 bp) and the plasmid pRHBSTW-00138_5 (97% coverage and 100% identity) harbored by Klebsiella quasipneumoniae subsp. similipneumoniae strains from hospital sewage in Japan and wastewater influent in the United Kingdom, respectively. The emergence of a human pathogenic E. coli clinical isolate with the bla VEB-1 -carrying plasmid in the B2-ST95 worldwide pandemic lineage, characterized by the virulence potential of ExPEC or UPEC but a low prevalence of antimicrobial resistance, would raise public health concerns. IMPORTANCE ESBLs are plasmid-mediated enzymes that confer resistance to clinically significant antimicrobial agents, such as broad-spectrum cephalosporins. Recently, the rapid spread of CTX-M-type ESBL-producing E. coli has become a global issue, including in Japan, where ESBL production in human pathogenic E. coli , such as the ExPEC and UPEC lineages, which typically harbor several virulence genes, is a severe public health concern. To date, VEB (Vietnamese extended-spectrum β-lactamase) producers have been found only in hospital wastewater and rivers in Japan. Thus, we describe the first detection of a very rare human-derived blaVEB-1 gene in the E. coli B2-ST95 pandemic clonal lineage that is highly associated with ExPEC and UPEC in a Japanese clinical setting. Furthermore, we characterized the genomic features of plasmids harboring the class 1 integron-borne blaVEB-1. Our findings highlight the significance of closely monitoring ESBL-producing E. coli isolates to prevent the potential dissemination of this resistance determinant in Japan.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (52)
Paul Turner
University of Oxford
Ørjan Samuelsen
Professor
UiT The Arctic University of Norway
Helena Seth-Smith
Co-Leader of Microbial Genomics Devision
University of Zurich
Nicole Stoesser
Associate Professor
University of Oxford
Amy Mathers
Professor
University of Virginia
Michael Bachman
Assistant Professor
University of Michigan
francesco pomilio
Head of Unit
Istituto Zooprofilattico Sperimentale dell'Umbria e delle Marche
Sandra Reuter
Research Group Leader
University Medical Center Freiburg
Takemasa Sakaguchi
-
Yukari Sato
Assistant professor
Tohoku University
Benjamin P. Howden
-
Koji Yahara
Group Leader
National Institute of Infectious Diseases
Arnfinn Sundsfjord
-
Alexandra Chiaverini
Ricercatore Sanitario (Cat. DS6) Veterinario
Istituto Zooprofilattico Sperimentale dell'Umbria e delle Marche
Sam Lipworth
University of Oxford
Andrew McArthur
Professor
McMaster University
M. Estée Török
University of Cambridge
Charlene Rodrigues
Assistant Professor in Microbial Genomics
London School of Hygiene & Tropical Medicine
Adrian Egli
Professor
University of Zurich
Kathryn Holt
Professor (Research)
MONASH UNIVERSITY
Leah Wendy Roberts
Queensland University of Technology
Daniela Maria Cirillo
Head of Unit
Ospedale San Raffaele
Tommaso Giani
Associate Professor
University of Florence
Teresa M. Coque
-
Marianne Sunde
Norwegian Veterinary Institute
Gian Maria Rossolini
Professor
University of Florence
Jukka Corander
University of Oslo
Miki Kawada-Matsuo
Hiroshima University
Susana Campino
London School of Hygiene & Tropical Medicine
Iren H. Löhr
Stavanger University Hospital
D. Sassera
University of Pavia
Stephen Baker
University of Cambridge School of Clinical Medicine
Kelly L Wyres
MONASH UNIVERSITY
Andrea Spitaleri
Researcher
Human Technopole
Hitoshi Komatsuzawa
Hiroshima University Graduate School of Biomedical and Health Sciences
Norelle Sherry
Deputy Director
University of Melbourne
Eva Heinz
Senior Lecturer
University Of Strathclyde
Melese Hailu Legese
Lecturer
Uppsala Universitet Uppsala biomedicinska centrum
Marisa Haenni
-
Sylvain Brisse
Université Paris Cité
Edward Feil
Professor at Department of Life Sciences
University of Bath
Patrick N. A. Harris
University of Queensland
Taane Clark
Professor of Genomics and Global Health
London School of Hygiene & Tropical Medicine
Claire Gorrie
University of Melbourne
Joao Perdigao
Professor do ensino Básico e Secundário
Ministério da Educação
Shizuo Kayama
National Institute of Infectious Diseases
Satoshi Nakano
Visitting Researcher
Nagoya University
Hirokazu Yano
Senior Research Fellow
National Institute of Infectious Diseases
Nicholas Thomson
Head of Programme
Wellcome Sanger Institute
Harry Thorpe
University of Oslo
Nicholas Feasey
Professor
Liverpool School of Tropical Medicine
David Aanensen
Professor
University of Oxford
Make your next move.
Prepare your application
Review drafts before you send them.